Dr. Jun Yoshino
Associate Professor of Medicine | Washington University School of Medicine
About
Lead author of Yoshino et al. 2021 (Science), a placebo-controlled human NMN trial in postmenopausal women with prediabetes. The trial reported improved muscle insulin sensitivity and signalling after 250mg/day NMN for 10 weeks.
Key contributions
- Yoshino 2021 NMN postmenopausal trial
- NAD+ intermediates therapeutic potential review
- Insulin sensitivity NAD+ biology
Publications in our knowledge base (11)
Every paper below is cited at least once across NMN Malaysia articles. Click any title to read the source on PubMed/DOI and see the cluster of articles that depend on its findings.
- Systemic nicotinamide mononucleotide administration to mitigate post-cardiac arrest brain injury in mice
- Preclinical animal study in PLoS One (2025) investigating NAD+/NMN pathway mechanisms
- Findings inform translational rationale; not yet replicated in humans
- Mechanistic data on tissue-specific NAD+ effects
- Adipocyte-specific inactivation of NAMPT, a key NAD(+) biosynthetic enzyme, causes a metabolically unhealthy lean phenotype in female mice during aging
- Preclinical animal study in Am J Physiol Endocrinol Metab (2024) investigating NAD+/NMN pathway mechanisms
- Findings inform translational rationale; not yet replicated in humans
- Mechanistic data on tissue-specific NAD+ effects
- Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men
- Mechanistic study in Endocr J (2024) on NAD+/sirtuin/longevity biology
- Adds to the foundational literature underlying NMN supplementation rationale
- First author: Yamaguchi S
- Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
- 10 weeks of 250 mg/day NMN improved muscle insulin sensitivity in prediabetic postmenopausal women
- First placebo-controlled NMN trial in women
- Skeletal muscle insulin signalling and remodelling improved
- Response to Comment on "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women"
- Authors' published Response to Comment defending the Yoshino 2021 NMN muscle-insulin-sensitivity trial in Science (2021)
- A correspondence/letter, not an original study; presents no new trial data
- Useful for understanding the scientific debate around the original prediabetic-women NMN trial
- Slc12a8 is a nicotinamide mononucleotide transporter
- Identified Slc12a8 as putative direct NMN transporter in mice
- Controversial - disputed by Schmidt & Brenner 2019
- Important context for sublingual vs oral debate
- Reply to: Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter
- Mechanistic study in Nat Metab (2019) on NAD+/sirtuin/longevity biology
- Adds to the foundational literature underlying NMN supplementation rationale
- First author: Grozio A
- NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR
- Authoritative comparison of NMN and NR mechanisms
- Tissue distribution and pharmacokinetics
- Most-cited NMN vs NR review
- Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice
- 12-month NMN administration suppressed age-associated weight gain in mice
- Improved energy metabolism, insulin sensitivity, plasma lipid profile, mitochondrial function
- Foundation animal study cited in most NMN human trial rationales
- SIRT1-Mediated eNAMPT Secretion from Adipose Tissue Regulates Hypothalamic NAD+ and Function in Mice
- Preclinical animal study in Cell Metab (2015) investigating NAD+/NMN pathway mechanisms
- Findings inform translational rationale; not yet replicated in humans
- Mechanistic data on tissue-specific NAD+ effects
- Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice
- Preclinical animal study in Cell Metab (2011) investigating NAD+/NMN pathway mechanisms
- Findings inform translational rationale; not yet replicated in humans
- Mechanistic data on tissue-specific NAD+ effects
Why their work matters for Malaysian buyers
Dr. Jun Yoshino's research forms part of the evidence base we use to evaluate NMN and NR products available in Malaysia. When we make claims about dose ranges, safety, mechanism, or efficacy on this site, those claims trace back through papers like the ones above. The Malaysian regulatory framework (NPRA notification, JAKIM halal certification) does not perform efficacy review on supplements - buyers must do their own evidence weighting. Researcher profiles help you verify that the underlying science is robust, not just marketing.
How we cite this work
Every NMN Malaysia article that depends on findings from Dr. Jun Yoshino's lab carries an inline citation linking to a structured PubMed entry. You can verify any claim by clicking the citation and reading the source. This cited-research model is the bedrock of our editorial policy - see the 4-step review process for how we handle every health claim.
Related researchers
Browse other profiles: David Sinclair | Shinichiro Imai | Jun Yoshino | Charles Brenner | all profiles.